Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Gastric Cancer, Gastric Adenocarcinoma, Gastric (Stomach) Cancer, Gastroesophageal Adenocarcinoma, Gastroesophageal Cancer (GC), Gastroesophageal Junction (GEJ) Adenocarcinoma, Gastroesophageal Junction (GEJ) Cancer, Gastrointestinal Cancer Metastatic and 6 more
- Main trialPhase 1/2
- “This study is looking at how safe BHB810 is in adults with gastric and gastroesophageal adenocarcinoma (GEJ). The purpose of this study is also to look at: how well the study drug works, how the study drug moves into, through, and out of the body, and how your body reacts to the study drug. Participants will get an IV infusion of BHB810 every 2 weeks while on study treatment.”In the company’s words, NCT07529808 on ClinicalTrials.gov
Other drugs for Gastric Cancer
- CAM2029Camurus AB · Phase 3
- Disitamab VedotinRemeGen · Phase 3
- RYZ101RayzeBio, Inc. · Phase 3
- ZanidatamabJazz Pharmaceuticals · Phase 3
- M108FutureGen Biopharmaceutical (Beijing) Co., Ltd · Phase 3
- RilvegostomigAstraZeneca · Phase 3
Coming up1
- Dec 2028Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | Dec 2028 | Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026